Insmed

Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2017. The company specializes in developing therapeutics aimed at restoring the biological balance in damaged, diseased, and dying cells. Adrestia Therapeutics is recognized for its expertise in synthetic rescue, an innovative approach that decodes complex genetic networks to identify novel treatment strategies for various diseases. In addition to therapeutic development, the company provides basic and applied research, as well as experimental development services tailored to the biotechnology industry.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

Celtrix is a biopharmaceutical company focused on developing novel therapeutics for the treatment of seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging.